[PDF][PDF] Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
…, GK Ellis, PH Petra, LM Peterson, EK Schubert… - J Clin Oncol, 2006 - academia.edu
Purpose In breast cancer,[18F] fluoroestradiol (FES) positron emission tomography (PET)
correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We …
correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We …
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
…, T Lawton, K Yagle, EK Schubert… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The PET compound 18 F-fluoroestradiol ( 18 F-FES) has been developed and tested as an
agent for the imaging of estrogen receptor (ER) expression in vivo. F-FES uptake has been …
agent for the imaging of estrogen receptor (ER) expression in vivo. F-FES uptake has been …
Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy
…, A Charlop, TJ Lawton, EK Schubert… - Journal of Nuclear …, 2002 - Soc Nuclear Med
Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy
followed by definitive surgery. The factors influencing the response of LABC to presurgical …
followed by definitive surgery. The factors influencing the response of LABC to presurgical …
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
…, JR Gralow, GK Ellis, EK Schubert… - Journal of Nuclear …, 2003 - Soc Nuclear Med
Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy
followed by definitive surgery. The factors influencing the response of LABC to presurgical …
followed by definitive surgery. The factors influencing the response of LABC to presurgical …
[HTML][HTML] Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally …
…, WE Barlow, BF Kurland, EK Schubert… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Purpose Patients with locally advanced breast carcinoma (LABC) receive preoperative
chemotherapy to provide early systemic treatment and assess in vivo tumor response. Serial …
chemotherapy to provide early systemic treatment and assess in vivo tumor response. Serial …
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic …
HM Linden, BF Kurland, LM Peterson, EK Schubert… - Clinical Cancer …, 2011 - AACR
Purpose: To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen
receptor (ER) binding differ between types of standard endocrine therapy. …
receptor (ER) binding differ between types of standard endocrine therapy. …
PennPET explorer: human imaging on a whole-body imager
…, MJ Parma, DA Pryma, EK Schubert… - Journal of Nuclear …, 2020 - Soc Nuclear Med
The PennPET Explorer, a prototype whole-body imager currently operating with a 64-cm axial
field of view, can image the major body organs simultaneously with higher sensitivity than …
field of view, can image the major body organs simultaneously with higher sensitivity than …
SUV varies with time after injection in 18F-FDG PET of breast cancer: characterization and method to adjust for time differences
…, J Tseng, LK Dunnwald, EK Schubert… - Journal of Nuclear …, 2003 - Soc Nuclear Med
The purpose of this study was to measure how 18 F-FDG PET standardized uptake values (SUVs)
change over time in breast cancer and to examine the feasibility of a method to adjust …
change over time in breast cancer and to examine the feasibility of a method to adjust …
Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy
SE Stafford, JR Gralow, EK Schubert, KJ Rinn… - Academic radiology, 2002 - Elsevier
RATIONALE AND OBJECTIVES: The authors performed this study to determine the feasibility
of using quantitative 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission …
of using quantitative 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission …
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of …
…, HM Linden, VK Gadi, BF Kurland, EK Schubert… - Clinical Cancer …, 2011 - AACR
Purpose: Changes in tumor metabolism from positron emission tomography (PET) in locally
advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are …
advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are …